A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer

Authors

Martin Sebastian (ORCID: https://orcid.org/0000-0002-0404-7741)
Akin Atmaca
Alinta Hegmane
Kenneth J. O’Byrne (ORCID: https://orcid.org/0000-0002-6754-5633)
Emilio Esteban (ORCID: https://orcid.org/0000-0002-2980-5254)
Dimitriοs Ziogas (ORCID: https://orcid.org/0009-0003-3103-2638)
Margarita Majem (ORCID: https://orcid.org/0000-0002-9919-7485)
Constantin Volovăț (ORCID: https://orcid.org/0000-0003-1582-0135)
Giuseppe Lo Russo (ORCID: https://orcid.org/0000-0003-3224-2728)
Cheen Leng Lee

Institutions

Goethe University Frankfurt (DE)
National and Kapodistrian University of Athens (GR)
Greenslopes Private Hospital (AU)
Hospital de Sant Pau (ES)
Penang Adventist Hospital (MY)
Grigore T. Popa University of Medicine and Pharmacy (RO)
Riga East University Hospital (LV)
University Hospital Frankfurt (DE)
Hospital Universitario Central de Asturias (ES)
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Frankfurt Cancer Institute (DE)

Publication Details

Journal: Future Oncology
Published: 2025-12-12
DOI: https://doi.org/10.1080/14796694.2025.2597404
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer

Martin Sebastian, Akin Atmaca, Alinta Hegmane, Kenneth J. O’Byrne et al.

Dec 12, 2025

Future Oncology

Cancer Immunotherapy and Biomarkers

article

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer

Martin Sebastian, Akin Atmaca, Alinta Hegmane, Kenneth J. O’Byrne, Emilio Esteban, Dimitriοs Ziogas, Margarita Majem, Constantin Volovăț, Giuseppe Lo Russo, Cheen Leng Lee

December 12, 2025article en

Abstract

No abstract available for this paper.

Future OncologyVol. 21(30)

Goethe University Frankfurt (DE), National and Kapodistrian University of Athens (GR), Greenslopes Private Hospital (AU), Hospital de Sant Pau (ES), Penang Adventist Hospital (MY), Grigore T. Popa University of Medicine and Pharmacy (RO), Riga East University Hospital (LV), University Hospital Frankfurt (DE), Hospital Universitario Central de Asturias (ES), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Frankfurt Cancer Institute (DE)

Openalex Percentile: Top 45%

Cancer Immunotherapy and Biomarkers

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer — Martin Sebastian, Akin Atmaca, et al. · Future Oncology (2025) | TGRS Research Map | TGRS